New hope for frail lymphoma patients: drug combo shows promise
NCT ID NCT06045247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding the drug epcoritamab to a standard chemotherapy combination (R-miniCVP) can better control newly diagnosed diffuse large B-cell lymphoma in older or frail patients who cannot take strong chemotherapy. The study will enroll 40 adults and also monitor safety. The goal is to find a gentler but effective treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab (a drug given under the skin) plus rituximab, cyclophosphamide, vincristine, and prednisone (given by vein or mouth)
What this could lead to
If it works, this could offer a more effective and safer treatment option for older or frail patients with a common type of lymphoma who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact